Notification Regarding the Progress of Phase III Clinical Trials of Cancer Peptide Vaccine ITK-1 in Patients with Castration-Resistant Prostate Cancer

Regarding the ongoing phase III placebo-controlled, double-blinded comparative study of peptide vaccine ITK-1 for patient with prostate cancer, which was first licensed out to FUJIFILM Corporation by our company and then conduction of the phase III study was consigned to GreenPeptide, we have received the results of interim analysis evaluation related to efficacy and safety from the Data and Safety Monitoring Committee, which is a third-party group. We have also received their recommendation to continue the current study.

Under the recommendation, we will conduct the clinical study with sufficient caution as to the safety of the cancer peptide vaccine.